Abstract | OBJECTIVE: DESIGN: A decision analysis and Markov model that described the natural history of the therapeutic process. The Markov model contained two treatment arms ( interferon-alpha and hydroxyurea) and eight states of health (complete hematologic remission with cytogenetic response, complete hematologic remission without cytogenetic response, partial hematologic remission, chronic phase without hematologic remission, accelerated phase, blast crisis, bone marrow transplantation, and death). Probabilities, costs, and utilities were obtained from published clinical studies and clinical investigators. MEASUREMENT: Quality-adjusted years of life saved and costs and qualities discounted at 5% per year. SETTING: University medical centers in North America and Europe. PATIENTS: Meta-analysis of results from patients studied in clinical trials. RESULTS: CONCLUSION:
|
Authors | M W Kattan, Y Inoue, F J Giles, M Talpaz, H Ozer, F Guilhot, E Zuffa, S L Huber, J R Beck |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 125
Issue 7
Pg. 541-8
(Oct 01 1996)
ISSN: 0003-4819 [Print] United States |
PMID | 8815752
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Interferon-alpha
- Hydroxyurea
|
Topics |
- Antineoplastic Agents
(economics, therapeutic use)
- Cost-Benefit Analysis
- Decision Support Techniques
- Humans
- Hydroxyurea
(economics, therapeutic use)
- Interferon-alpha
(economics, therapeutic use)
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy)
- Leukemia, Myeloid, Chronic-Phase
(drug therapy)
- Markov Chains
- Middle Aged
- Quality-Adjusted Life Years
|